美股医药股延续涨势，阿斯利康涨超6%，赛诺菲安万特、葛兰素史克涨近4%。 来源：滚动播报 ...

(Reuters) -Global drugmakers are scrambling to shore up their U.S. manufacturing capacity and domestic inventory as the Trump administration moves ahead with a 100% tariff on imported branded and patented drugs, starting October 1. The sweeping measure has triggered a flurry of activity across the industry, including fast-tracking U.S. manufacturing projects, price cuts and direct-to-consumer sales. Here's what drugmakers are doing to mitigate supply-chain risks and reassure investors: Pfizer Pfizer re ...

白宫推出药品购买网站后，阿斯利康股价上涨3.6%。 来源：滚动播报 ...

Core Viewpoint - GSK is transitioning from American Depositary Receipts (ADRs) on Nasdaq to a direct listing of ordinary shares on the New York Stock Exchange, coinciding with the departure of CEO Emma Walmsley and the appointment of Luke Miels as her successor [1][3]. Company Developments - GSK's CEO Emma Walmsley will leave at the end of the year after nine years, having led the company through its demerger, which resulted in the formation of Haleon as a separate entity [1]. - Luke Miels, the current chief commercial officer, will take over as CEO, having previously been with AstraZeneca (AZ) [1]. Market Reactions - The announcement of GSK's move was positively received by investors, resulting in a 0.8% increase in shares on the following Monday [3]. - The shift to a direct listing is expected to attract new U.S. investors, particularly if AZ gains membership in the S&P 500 [3]. Industry Trends - There is a growing trend of UK-listed companies moving their primary listings to the U.S., with several notable companies, including BHP Group, Ferguson, and CRH, having made similar transitions recently [6][7][8][9]. - The movement of companies away from the London Stock Exchange (LSE) has raised concerns about the future of the UK market, especially as major firms like Flutter Entertainment and Arm Holdings have opted for U.S. listings [10][11][12]. Implications for AstraZeneca - AstraZeneca's potential move to the U.S. market has been a topic of discussion, with CEO Pascal Soriot expressing interest in relocating the company's stock market listing [4][5]. - Despite concerns, AZ emphasized that its status as a UK-listed company would remain unchanged, aiming to attract a broader mix of global investors [15]. - AZ's current price-to-earnings ratio is competitive compared to both European and U.S. peers, indicating that the move is not necessarily driven by a desire for a higher stock rating [16].

Core Insights - AstraZeneca's stock has shown strong performance, rising 3.49% for three consecutive days, indicating investor confidence amid market volatility [1] - The company plans to directly list on the New York Stock Exchange, replacing its current American Depositary Receipts (ADR) on NASDAQ, aiming to attract more global investors while maintaining its UK listing status [1] - AstraZeneca intends to invest $50 billion in manufacturing and R&D in the U.S. by 2030 to maintain its market leadership amid increasing competition in generics [1] Market Position - The U.S. is AstraZeneca's largest single market, contributing over 40% of its revenue, with a goal to achieve $80 billion in annual revenue by 2030 [2] - The company has reported positive clinical trial results for its HER2-positive early breast cancer drug, trastuzumab, enhancing its innovative drug portfolio and potentially transforming treatment options [2] - AstraZeneca's strategic shift towards the U.S. market is expected to bolster its appeal in global capital markets and position it favorably in international competition [2]

Group 1 - AbCellera Biologics Inc. (ABCL) has shown strong year-to-date performance, with a return of approximately 66.2%, outperforming the Medical sector, which has lost an average of 2.7% [4] - The Zacks Rank for AbCellera Biologics Inc. is currently 2 (Buy), indicating a positive earnings outlook based on earnings estimates and revisions [3][4] - The Zacks Consensus Estimate for ABCL's full-year earnings has increased by 8.3% over the past quarter, reflecting improved analyst sentiment [4] Group 2 - AbCellera Biologics Inc. is part of the Medical - Biomedical and Genetics industry, which consists of 482 stocks and currently ranks 78 in the Zacks Industry Rank [6] - The average return for stocks in the Medical - Biomedical and Genetics industry this year is 3.2%, indicating that ABCL is performing better than its peers in this specific industry [6] - Another notable stock in the Medical sector, Astrazeneca (AZN), has returned 13.1% year-to-date and also holds a Zacks Rank of 2 (Buy) [5][6] Group 3 - Investors should continue to monitor AbCellera Biologics Inc. and Astrazeneca for potential sustained strong performance in the Medical sector [7]

AstraZeneca's move to upgrade its listing in the U.S. risks pulling liquidity away from London's stock market and could pave the way for other large companies to follow suit, analysts, investors and a... ...

Group 1: Granolas Sector Analysis - The Granolas sector, which includes major European companies, has underperformed the European market index by approximately 25% since early 2024, with its market capitalization dropping from 27% to 20% of the overall European market [2] - Despite weak stock performance, Granolas' earnings have not deteriorated, with an expected earnings growth rate of 8% for 2025, while overall European market earnings are projected to remain flat [2] - The valuation issues of Granolas have been corrected, with the current price-to-earnings ratio at a 6% discount compared to the median of the past 10 years, indicating a return to reasonable levels [2] - Granolas' free cash flow yield has improved, and cash reserves on the balance sheet increased from €91 billion in 2023 to €106 billion in 2024, with stock buybacks projected to rise from €23 billion in 2023 to an annualized €36 billion in 2025 [2] Group 2: French Stock Market Outlook - The French stock market has underperformed the market by about 15% over the past two years, with bank stocks lagging behind Eurozone peers by as much as 30% [4] - Currently, the French stock market is trading at a significant discount compared to the STOXX 50 index, a situation historically seen only during major crises [4] - Morgan Stanley believes that the long-term bond yields in France are unlikely to continue rising, and the negative impact from the government's failure to pass a confidence vote may temporarily dissipate, presenting attractive investment opportunities [4] - Despite high uncertainty, including potential future confidence votes, there is a possibility of reaching a budget plan acceptable to the market, and any negative impact from re-elections on risk assets may be short-lived [4]

Core Viewpoint - The company has terminated its collaboration with AstraZeneca on the development, production, and commercialization of the ChAdOx1 adenovirus vector COVID-19 vaccine due to changes in the epidemic strain and market environment, as well as resource allocation considerations [1] Group 1: Collaboration Termination - The termination of the collaboration is a cautious decision based on the evolving COVID-19 vaccine landscape and market conditions [1] - The company has signed a License Termination Agreement with AstraZeneca [1] Group 2: Future Focus - The company currently has nearly 30 projects in development, covering important categories such as multivalent vaccines and innovative vaccines [1] - Future resource allocation will concentrate on the research and industrialization of multivalent vaccines, adult vaccines, innovative vaccines, and therapeutic vaccines to enhance core competitiveness [1]

Core Viewpoint - AstraZeneca plans to directly list its common stock on the New York Stock Exchange starting February 2, 2026, replacing its current American Depositary Receipt (ADR) trading model, aiming to leverage the depth and liquidity of the U.S. capital markets to expand its investor base and enhance stock attractiveness [1][2]. Group 1: Strategic Adjustments - The transition to a direct listing is a significant adjustment that requires approval at the upcoming shareholders' meeting on November 3, 2025 [2]. - AstraZeneca's stock price rose by 0.8% on September 29, with a market capitalization of approximately £171 billion [2]. - The company will maintain its headquarters in the UK and its primary listing in London, alleviating concerns about a potential "exit" from the UK [2]. Group 2: Financial Performance - For the first half of 2025, AstraZeneca reported total revenue of $28.045 billion, an 11% year-over-year increase (at constant exchange rates), with core EPS reaching $4.66, up 17% [2]. - The U.S. market is crucial for AstraZeneca, contributing 43% of the company's revenue last year, with expectations that this will rise to 50% by 2030 [2]. Group 3: Investment and Market Position - The company plans to invest $50 billion in manufacturing and R&D by 2030 to mitigate potential tariff risks and drive revenue growth to $80 billion by that year [3]. - AstraZeneca's shift to a direct listing on the NYSE is expected to improve trading efficiency and market valuation compared to its previous ADR model [3]. - The decision to pause a £200 million R&D project in Cambridge highlights the challenges the UK faces in attracting large multinational investments [3].